Phase IIb

Related by string. phase IIb * phase : Phase III clinical trials / IIB : Phase IIb clinical * Phase IIb trial . phase IIb clinical . Phase IIb trials . Phase IIb clinical trials . initiate Phase IIb . phase IIb trial . Phase IIb Trial . Phase IIb Clinical Trial . randomized Phase IIb . modified REGENESIS Phase IIb . phase IIb study . Phase IIb dose . phase IIb III . Phase IIb III *

Related by context. All words. (Click for frequent words.) 82 Phase IIa 82 Phase IIb clinical 82 Phase 2b 82 Phase III clinical 82 Phase 2b study 81 Phase IIb trial 81 pivotal Phase III 80 Phase III 80 Phase 2a 79 phase IIb 79 Phase Ib 78 Phase 2b trial 78 phase IIa 77 Phase IIa trial 77 Phase 2b clinical 77 Phase 1b 76 Phase 2a trial 76 Phase 2a clinical 76 Phase II 75 phase IIa clinical 75 Phase IIa clinical 75 Phase Ib clinical 74 phase IIb clinical 74 Phase 1b clinical 74 clinical trial 73 Phase III clinical trials 73 Phase III trials 73 pivotal Phase 73 Phase 1b trial 72 phase 2a 72 Phase III pivotal 71 Phase IIIb clinical 71 dose escalation trial 71 Phase IIB 71 randomized Phase 70 Phase 1a 70 Phase IIb trials 70 confirmatory Phase III 70 Phase Ib study 70 Phase Ib II 69 Phase #b/#a 69 Phase IIa trials 69 multiple ascending dose 69 placebo controlled Phase 69 Phase Ia 69 phase Ib 69 phase IIb trial 68 Phase 2b clinical trials 68 clinical trials 68 multicenter Phase 67 registrational 67 Phase IIIb 67 confirmatory Phase 3 67 Phase 1a clinical 67 BRIM3 67 randomized Phase IIb 66 multicenter Phase II 66 dose escalation Phase 66 double blind placebo 66 multicenter clinical 66 dose escalation study 66 placebo controlled 66 Phase 66 JAK inhibitor 66 NO# [002] 66 bicifadine 66 Phase III Clinical Trial 66 Phase IIb clinical trials 66 placebo controlled Phase III 65 preclinical 65 INCB# [001] 65 BRIM2 65 randomized controlled Phase 65 Phase #/#a 65 SUCCEED trial 65 placebo controlled clinical 65 APEX PD 65 initiate Phase 65 randomized placebo controlled 65 dose escalation 65 GALNS 65 randomized Phase 2b 65 TMC# [002] 65 randomized double 65 Phase IIb Trial 65 single ascending dose 64 PRX # 64 Phase Ib clinical trials 64 pivotal bioequivalence 64 dose escalation clinical 64 phase IIb study 64 II Clinical Trial 64 elotuzumab 64 FOLOTYN ® 64 IIa trial 64 Phase III confirmatory 64 Pivotal Trial 64 randomized multicenter 64 oral ridaforolimus 64 PREOS 64 teduglutide 64 Investigational Device Exemption IDE 64 initiate Phase IIb 64 Corlux 64 randomized Phase III 64 Zenvia Phase III 64 Phase 2b kidney transplant 63 IND enabling 63 cannabinor 63 clinical pharmacology studies 63 PSN# [002] 63 blind randomized placebo 63 tolerability 63 mipomersen 63 Phase 2b randomized 63 ENDEAVOR IV 63 blinded randomized placebo controlled 63 INCB# [002] 63 multicenter randomized double 63 KRN# 63 ozarelix 63 COMFORT II 63 BCX# 63 preclinical studies 63 Initiate Phase 63 IIa clinical 63 MEND CABG 63 randomized clinical 63 Pivotal Phase 63 phase IIb III 62 Phase III randomized controlled 62 Phase IIb III 62 Pivotal Phase III 62 phase IIIb 62 NGX# 62 double blinded placebo 62 Dacogen injection 62 registrational trial 62 glufosfamide 62 multicentre randomized 62 ongoing Phase 1b 62 Cloretazine R VNP#M 62 ocrelizumab 62 Phase III Trial 62 IND submission 62 Phase Ib IIa 62 multicenter phase 62 Zerenex 62 multicenter randomized Phase 62 forodesine 62 investigational drug 62 PRE SURGE 62 multicenter 62 Amrubicin 62 TG MV 62 Phenoptin 62 AEGR 62 AeroLEF TM 62 multicenter randomized placebo controlled 62 ADVANCE PD 62 Fx #A 62 dose cohorts 62 Phase 2a clinical trials 62 HspE7 62 CRx 62 Phase 1b dose escalation 62 pharmacokinetic PK study 62 Phase IIIb study 62 multicenter Phase III 62 lomitapide 62 Aurexis 62 alvespimycin 62 deforolimus 62 dirucotide 61 NP2 Enkephalin 61 albinterferon alfa 2b 61 initiate Phase Ib 61 phase Ib clinical 61 AQ4N 61 IDX# 61 PXD# 61 randomized controlled 61 axitinib 61 IIa clinical trial 61 ILLUMINATE 61 Initiated Phase 61 selective androgen receptor modulator 61 PREOS R 61 HuMax EGFr 61 AZILECT R 61 celgosivir 61 dose cohort 61 masked placebo controlled 61 Pivotal Study 61 Elagolix 61 Ostarine 61 Phase IIa clinical trials 61 Phase III psoriasis 61 MAA submission 61 prospective multicenter 61 pharmacokinetic 61 BLA filing 61 HGS ETR1 61 opioid induced bowel dysfunction 61 VEGF Trap 61 investigational compound 61 Phase III randomized 61 dyskinesia PD LID 61 oral deforolimus 61 virus HCV protease inhibitor 61 tesmilifene 61 Phase III Clinical Trials 61 prospective randomized 61 CoFactor 61 lintuzumab 61 R#/MEM # 61 RDEA# 61 Augment Injectable 61 BLA submission 61 unblinding 61 Phase #b/#a trial 61 rALLy clinical trial 61 pharmacokinetic studies 61 Archexin 61 RE SURGE 61 denufosol 61 PDE4 inhibitor 61 enzastaurin 61 randomized controlled multicenter 60 pharmacokinetics PK 60 perifosine 60 L BLP# 60 huC# DM4 60 TMC# C# 60 mertansine 60 cetrorelix 60 diabetic neuropathic pain 60 rNAPc2 60 HGS# 60 PEG Interferon lambda 60 alvimopan 60 Androxal TM 60 DR Cysteamine 60 GLP toxicology studies 60 Randomized Phase 60 eniluracil 60 Bicifadine 60 confirmatory clinical 60 PFO migraine 60 APPRAISE 60 pharmacokinetic PK 60 MERLIN TIMI 60 double blinded randomized 60 midstage trials 60 Triolex 60 PS# [001] 60 initiate Phase 2b 60 Phase IIa proof 60 Phase IIb Clinical Trial 60 CR# vcMMAE 60 ganetespib 60 viral kinetic 60 MIST II 60 rALLy trial 60 Desmoteplase 60 XL# [003] 60 RSD# oral 60 budesonide foam 60 BAY #-# 60 oral prodrug 60 CB2 selective receptor agonist 60 controlled multicenter 60 brivaracetam 60 Phase 2b Clinical Trial 60 HuMax CD# 60 vidofludimus 60 ascending dose 60 Mipomersen 60 velafermin 60 IMGN# 60 visilizumab 60 nitazoxanide 60 ATL# [001] 60 OvaRex ® MAb 60 PRT# 60 PROPEL trial 60 Traficet EN 60 TASKi2 60 LUX Lung 60 MOZOBIL 60 HCV SPRINT 60 ITAX 60 RG# [001] 60 ANCHOR trial 60 placebo controlled randomized 60 Alzhemed TM 60 Phase 1b clinical trials 60 QLT# 60 ADX# 60 IMA# 60 Clinical Trial 60 AeroLEF 60 ofatumumab 60 relapsed refractory multiple myeloma 60 Asentar 60 eltrombopag 60 Urocidin 60 volociximab 60 Phase III placebo controlled 59 stated Michelle Berrey 59 subcutaneous formulation 59 docetaxel Taxotere R 59 Exherin TM 59 preclinical efficacy 59 label multicenter 59 midstage clinical 59 fostamatinib 59 ICA # 59 ZYBRESTAT 59 PEG PAL 59 LibiGel ® 59 trodusquemine 59 ruxolitinib 59 multicenter prospective 59 OncoVEX GM CSF 59 valopicitabine 59 PHX# 59 multicenter randomized 59 AZILECT ® 59 PD LID 59 HuMax CD4 59 Phase IIb kidney transplant 59 initiate Phase 1b 59 MEK inhibitor RDEA# 59 blind randomized 59 Phase 2a Clinical Trial 59 acyclovir Lauriad R 59 Viramidine 59 CLARITY study 59 TELCYTA 59 Phase #b/#a clinical 59 ISIS # 59 PANVAC VF 59 elagolix 59 Sym# 59 aclidinium bromide 59 DSMB 59 EndoTAG TM -1 59 LymphoStat B TM 59 unblinded 59 ularitide 59 CRMD# 59 Factor VIIa 59 incyclinide 59 reslizumab 59 metastatic castrate resistant 59 MAGE A3 ASCI 59 TLK# 59 AIR CF1 59 octreotide implant 59 evaluating tivozanib 59 TASKi3 59 metastatic hormone refractory 59 Alocrest 59 TBC# 59 ASA# 59 QNEXA 59 Locteron 59 BLOOM DM 59 Laquinimod 59 sapacitabine 59 GetGoal Phase III 59 Safinamide 59 CRLX# 59 tanespimycin 59 Phase III HEAT 59 Phase IIA 59 SinuNase 59 CEQ# 59 NDA submission 59 Phase III Pivotal 59 investigational humanized monoclonal antibody 59 CCR5 antagonist 59 PLK1 SNALP 59 custirsen 59 elacytarabine 59 Dyloject TM 59 unblind 59 Vitaxin 59 lorvotuzumab mertansine 59 dextromethorphan quinidine 59 Microplasmin 59 HCV RESPOND 2 59 Zenvia ™ 59 EVEREST II 59 omacetaxine mepesuccinate 59 MGCD# [001] 59 Amigal 59 prospective randomized placebo 59 APTIVUS 59 blinded randomized 59 Proxinium TM 59 nonclinical studies 59 Azedra 59 AzaSite Plus 59 BEMA TM Fentanyl 59 Plicera 59 GLPG# 58 Memryte 58 histone deacetylase HDAC inhibitor 58 Eniluracil 58 GAMMAGARD 58 riociguat 58 Oglemilast 58 ProLindac 58 ADAGIO study 58 EVIZON 58 severe hypercholesterolemia 58 methylnaltrexone 58 relapsed multiple myeloma 58 PEARL SC 58 EFAPROXYN 58 dosing cohorts 58 Phase #/#a trial 58 SYMMETRY trial 58 European Sepsis Trial 58 generation PNP inhibitor 58 vicriviroc 58 blinatumomab 58 Luveniq 58 Omigard 58 Marqibo 58 EOquin 58 treatment naïve genotype 58 treatment naive genotype 58 Fodosine 58 Feasibility Trial 58 MBP# [001] 58 investigational 58 LUMINATE 58 interferon gamma 1b 58 OLpur TM H2H 58 safety tolerability 58 Phase 2a Trial 58 EchoCRT 58 AZD# 58 ALN TTR# 58 IMC A# 58 Gabapentin GR 58 torezolid phosphate 58 IL# PE#QQR 58 LibiGel Phase III 58 Ozarelix 58 SCH # 58 preclinical toxicology 58 active comparator 58 ENDEAVOR III 58 Civacir 58 multicenter placebo controlled 58 pertuzumab 58 Randomized Phase II 58 PRECiSE 58 Cloretazine ® 58 trastuzumab emtansine T DM1 58 Serdaxin 58 compound INCB# 58 Dose Ranging Study 58 pradefovir 58 AZX# 58 blinded placebo controlled 58 PRESEPT 58 LEVADEX 58 AIR CF2 58 tezampanel NGX# 58 oral calcitonin 58 AP# [003] 58 arzoxifene 58 Aryplase 58 nab paclitaxel 58 PEP# [003] 58 DU #b 58 trastuzumab DM1 T DM1 58 investigational pan BCR 58 Capesaris 58 metastatic castration resistant 58 AZX# Phase 58 IIb clinical trial 58 tezampanel 58 CUSTOM III 58 Pirfenidone 58 ALKS 58 label multicenter Phase 58 bardoxolone 58 laquinimod 58 Phase 2b Trial 58 MEND CABG II 58 talactoferrin 58 tivozanib 58 Icatibant 58 SEPET TM 58 TH# [003] 58 ThermoDox R 58 Personalized Immunotherapy 58 HGS ETR2 58 prospective multicenter randomized 58 eprotirome 58 Completes Patient Enrollment 58 Investigational 58 Phase 2b Study 58 Viprinex 58 PROSTVAC TM 58 Vicinium TM 58 microplasmin 58 tramiprosate Alzhemed TM 58 randomized multicenter Phase III 58 CHAMPION PCI 58 aflibercept 58 Pimavanserin 58 PS# DARA 58 ProSavin 58 cancer neuroendocrine tumor 58 Multiple Ascending Dose 58 ELND# 58 teriflunomide 58 mGluR5 negative 58 ThermoDox ® 58 Efficacy Results 58 Relovair 58 BST CarGel R 58 Locteron ® 58 Annamycin 58 multicentre randomized double 58 multicenter study 58 multicenter randomized controlled 58 IPL# 58 darusentan 58 Æterna Zentaris 58 TACI Ig 58 confirmatory Phase 58 picoplatin 58 REOLYSIN ® 58 Phase 2b monotherapy 58 AEG# 58 initiated Phase Ib 57 Glybera R 57 neratinib 57 atrasentan 57 rindopepimut 57 assessing T DM1 57 carfilzomib 57 nalbuphine ER 57 Panzem R NCD 57 Hyphanox 57 NOX E# 57 CIP TRAMADOL ER 57 DASISION 57 fidaxomicin Phase 3 57 OPT CHF 57 Parkinson disease levodopa induced 57 TKM ApoB 57 PRTX 57 DSMB recommended 57 belinostat 57 oral methylnaltrexone 57 refractory CLL 57 tremelimumab 57 evaluating RDEA# 57 miconazole Lauriad ® 57 Gattex 57 Fibrillex TM 57 Maximum Tolerated Dose 57 dexanabinol 57 Phase 2a proof 57 ARRY 57 sNDA submission 57 Phase lll 57 SNT MC# 57 RSD# 57 APEX AMI trial 57 SAR# [004] 57 Quinamed 57 oral formulation 57 Clinical Trial Results 57 Dapagliflozin 57 investigational monoclonal antibody 57 Iluvien 57 Matrix Phase 2b 57 Restanza 57 AVADO 57 label dose escalation 57 telaprevir dosing 57 Trial Evaluating 57 multicenter multinational 57 Vicriviroc 57 TELINTRA 57 Study Evaluating 57 OvaRex R 57 IMC #B 57 ascending doses 57 metaglidasen 57 ONCONASE R 57 GEM OS1 57 CLIRS trial 57 Octreolin 57 Myocet 57 ORENCIA ® 57 FOLOTYN 57 Daclizumab 57 obatoclax 57 PEG SN# 57 blind placebo controlled 57 LBH# 57 TRO# 57 nonrandomized 57 relapsing multiple sclerosis 57 Phase III Trials 57 huN# DM1 57 MEK inhibitor 57 ecallantide 57 IIa trials 57 peginesatide 57 resminostat 57 abiraterone acetate 57 davunetide intranasal AL 57 thorough QT 57 LCP AtorFen 57 voreloxin 57 linaclotide 57 RELOVAIR ™ 57 prospective randomized controlled 57 SPIRIT FIRST 57 LymphoStat B 57 non nucleoside inhibitor 57 PDX pralatrexate 57 Adlea 57 COSIRA trial 57 efficacy endpoint 57 Zybrestat 57 metastatic HRPC 57 SPIRIT III 57 ENRICH trial 57 midstage studies 57 eculizumab 57 sunitinib malate 57 Virulizin R 57 ulimorelin 57 ganaxolone 57 NEBIDO 57 Meets Primary Endpoint 57 hypoxia activated prodrug 57 candidates Dyloject TM 57 dexpramipexole 57 dosing cohort 57 Topical Interferon Alpha 2b 57 PROMACTA 57 MAP# 57 T DM1 57 Vilazodone 57 Shigamabs ® 57 pomalidomide 57 Tezampanel 57 ABSORB trial 57 Omacetaxine 57 receptor tyrosine kinase inhibitor 57 IND Investigational New 57 RGB # 57 Cimzia TM 57 lesinurad 57 Ofatumumab 57 Phase #/#a clinical 57 CCX# 57 velafermin belinostat 57 Zelrix 57 EOquin TM 57 Tesetaxel 57 aclidinium 57 Phase III Psoriasis 57 voclosporin 57 apaziquone 57 Zensana TM 57 Allovectin 7 57 Dalbavancin 57 MAXY alpha 57 albiglutide 57 Hsp# Inhibitor 57 IMPACT DCM 57 DDP# 57 Darusentan 57 prospective randomized multicenter 57 Perifosine 57 GATTEX 57 AEZS 57 oral treprostinil 57 orBec 57 randomized blinded 57 Ophena 57 Proellex TM 57 Pivotal Clinical Trial 57 Cannabinor 57 GATTEX TM 57 Marketing Authorization Application 57 EINSTEIN DVT 57 fosbretabulin 57 PMA submission 57 TEMSO 57 GSK# [002] 57 PrevOnco ™ 57 integrase inhibitor 57 Blinatumomab 57 castrate resistant prostate cancer 57 safinamide 57 Onrigin 57 Zoraxel 57 Diamyd ® 57 afatinib 57 Ophena TM 57 New Drug Application 57 randomized 57 Prosaptide 56 Patient Enrollment 56 Ketotransdel 56 Synavive 56 CCX# B 56 PrevOnco 56 Firazyr 56 PSMA ADC 56 baminercept 56 PRECISE trial 56 PI3K/Akt pathway inhibitor 56 TORISEL 56 Allovectin 7 R 56 Torisel 56 Sorafenib HCC Assessment 56 PA# [002] 56 Acapodene 56 BrachySil TM 56 Empatic 56 ELACYT 56 cathepsin K inhibitor 56 olaparib 56 efficacy 56 RE LY ® 56 ILUVIEN ® 56 investigational oral 56 OHR/AVR# 56 Alpharadin 56 pegloticase 56 CA4P 56 PARTNER Trial 56 tiapamil 56 IMPACT IMmunotherapy 56 Ereska 56 Nexavar sorafenib 56 NUVIGIL 56 Milnacipran 56 Phase III VISTA 56 acyclovir Lauriad ® 56 KNS # 56 edoxaban 56 Clonicel 56 clevudine 56 Tovaxin 56 CIMZIA TM 56 EDEMA3 56 Clinical Study 56 RhuDex ® 56 subanalysis 56 betrixaban 56 Panzem R 56 ospemifene 56 randomized multicenter trial 56 subcutaneously administered 56 ofatumumab HuMax CD# 56 Targretin 56 PLX PAD 56 phase III ACCLAIM 56 LEVADEX ™ 56 STRIDE PD 56 Prostate AdenoCarcinoma Treatment 56 RE LY 56 Zenvia TM 56 Initiates Phase II 56 Diabetic Macular Edema 56 Apoptone 56 ACTEMRA TM 56 refractory metastatic colorectal cancer 56 Prodarsan 56 Ocrelizumab 56 multicentre 56 NKTR 56 maribavir 56 injectable formulation 56 VNP#M 56 isavuconazole 56 cell lymphoma CTCL 56 Azilect ® 56 Novolimus 56 Elocalcitol 56 Canvaxin 56 evaluating REVLIMID 56 CCR5 mAb 56 Board DSMB 56 ACAPODENE 56 rilonacept 56 interferon beta 1b 56 UVIDEM 56 Onco TCS 56 Allovectin 7 ® 56 daclizumab 56 Ceflatonin R 56 cetuximab Erbitux 56 ORENCIA R 56 mg/m2 cohort 56 Linaclotide 56 PROVENGE sipuleucel T 56 Phase III multicenter 56 trial evaluating PRX# 56 Veronate 56 ORMD 56 Serada 56 analgesic efficacy 56 PRIMO CABG2 56 Sapacitabine 56 Glufosfamide 56 Serdaxin ® 56 TASQ 56 palifosfamide 56 Fast Tracked Phase 56 Golimumab 56 Spiegelmer ® 56 darapladib 56 Urocortin 2 56 tolerated dose MTD 56 modified REGENESIS Phase IIb 56 Anturol 56 Aclidinium 56 pralatrexate injection 56 ocular formulation 56 TG# [003] 56 prospective multicentre 56 initiate Phase 2a 56 Phase IIa Clinical Trial 56 Aplidin 56 pharmacodynamic PD 56 lixisenatide 56 Ixempra 56 GRAVITAS trial 56 tolevamer 56 thymalfasin 56 Prospective Randomized 56 Dextofisopam 56 Genasense ® oblimersen 56 PRIMO CABG 56 NTx TM -# 56 vilazodone 56 MLN# 56 administered subcutaneously 56 dacetuzumab 56 monotherapy 56 JAK2 inhibitor 56 Azixa 56 LUVENIQ 56 NLX P# 56 HZT 56 XIENCE V Stent System 56 VA# [002] 56 SinuNase TM 56 HuLuc# 56 apremilast 56 Iluvien ® 56 randomized controlled clinical 56 Medidur TM FA 56 pralatrexate 56 TAXUS ATLAS 56 safety tolerability pharmacokinetics 56 Clevudine 56 Combination REOLYSIN R 56 REG2 56 Taxotere ® 56 midstage study 56 AMR# 56 nucleotide analog 56 mapatumumab 56 maximally tolerated dose 56 IMPACT DCM clinical 56 Alfimeprase 56 REVLIMID lenalidomide 56 LIALDA 56 GW# [003] 56 TOCOSOL Paclitaxel 56 FDA Investigational Device 56 alfimeprase 56 lead Aganocide compound 56 nalmefene 56 Denufosol 56 ABSORB clinical 56 FAME Study 56 AVN# [001] 56 efficacy tolerability 56 ancrod 56 Huntexil 56 varespladib 56 PRECISE Trial 56 THALOMID 56 LEVADEX TM 56 ritonavir boosted 56 Cethromycin 56 DB# [003] 56 Cleviprex TM clevidipine 56 Biologics License Application BLA 56 CONSERV 56 budesonide MMX 56 Insegia 56 zalutumumab 56 AIMM trial 56 LEP ETU 56 generation purine nucleoside 56 Achieves Primary Endpoint 56 Tanespimycin 56 randomized discontinuation trial 56 initiate Phase IIa 56 Stimuvax R 56 leading oral taxane 56 CDP# 56 Phase III ALLEGRO 56 Reverset 56 MIVI III 56 label multicenter randomized 56 ROCKET AF 55 OLYMPIA registry 55 R# #mg BID 55 oxymorphone ER 55 New Drug IND 55 trastuzumab DM1 55 HDAC Inhibitor 55 PEG IFN 55 OncoGel 55 ALN VSP Phase 55 ToGA 55 Opexa 55 Initiate Phase II 55 Viprinex TM 55 Stimuvax 55 OncoVex 55 MORAb 55 DEB# 55 ixabepilone 55 Neurodex 55 REVIVE Diabetes 55 satraplatin Phase 55 registrational studies 55 Anturol TM 55 TOLAMBA 55 FlutiformTM 55 Nasulin 55 Tavocept 55 BOLDER II 55 ORAL Sync 55 amrubicin 55 controlled multicenter Phase 55 bendamustine 55 refractory gout 55 vascular disrupting agent 55 Lupuzor 55 INT# [002] 55 Phase III metastatic melanoma 55 ONCONASE 55 Orazol 55 Phase 1b Clinical Trial 55 randomized multicentre 55 VALOR trial 55 LidoPAIN SP 55 midstage clinical trials 55 StemEx 55 adecatumumab 55 Vernakalant 55 PEG INTRON 55 recurrent malignant glioma 55 Phase IIb dose 55 Phase IIB clinical 55 lorcaserin Phase 55 Marketing Authorisation Application 55 dose dose escalation 55 symptomatic BPH 55 crizotinib PF # 55 blind multicenter 55 L MTP PE 55 atacicept 55 romidepsin 55 NVA# 55 preclinical pharmacokinetic 55 eosinophilic asthma 55 ARISE Phase III 55 Aflibercept 55 urocortin 2 55 tesetaxel 55 MoxDuo 55 XL# SAR# 55 MONOVISC

Back to home page